Who
Douglas M. Baker Jr.
Director
Company insider
Files Form 4 as: Director, Merck & Company; Director, Target; Exec Chairman of the Board, Ecolab; Director, U.S. Bancorp.
In numbers
- Trades disclosed
- 238
- Buys
- 2
- Sells
- 14
- Bought
- $1.4M
- Sold
- $188.3M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 7 Nov 2001
- Last trade
- 29 May 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 May 2026filed 2 Jun 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K1,853.1 at $118.72 | filing |
| 29 May 2026filed 2 Jun 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K1,853.1 at $118.72 | filing |
| 11 Mar 2026filed 13 Mar 2026 | TGT TargetMass, Grocery & Drug Retail | SEC FORM 4 Code A | —1,676 at $0.00 | filing |
| 11 Mar 2026filed 13 Mar 2026 | TGT TargetMass, Grocery & Drug Retail | SEC FORM 4 Code A | —1,676 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K2,863.09 at $76.84 | filing |
| 12 Mar 2025filed 14 Mar 2025 | TGT TargetMass, Grocery & Drug Retail | SEC FORM 4 Code A | —1,841 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Bought | $1.3M15,000 at $88.50 | filing |
| 31 May 2024filed 4 Jun 2024 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K1,752.43 at $125.54 | filing |
| 13 Mar 2024filed 15 Mar 2024 | TGT TargetMass, Grocery & Drug Retail | SEC FORM 4 Code A | —1,148 at $0.00 | filing |
| 26 May 2023filed 31 May 2023 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K1,980.73 at $111.07 | filing |
| 8 Mar 2023filed 10 Mar 2023 | TGT TargetMass, Grocery & Drug Retail | SEC FORM 4 Code A | —2,056 at $0.00 | filing |
| 27 May 2022filed 1 Jun 2022 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K2,363.56 at $93.08 | filing |
| 30 Mar 2022filed 31 Mar 2022 | TGT Targetoption or derivative · Mass, Grocery & Drug Retail | SEC FORM 4 Code M | —5,570 at $0.00 | filing |
| 30 Mar 2022filed 31 Mar 2022 | TGT TargetMass, Grocery & Drug Retail | SEC FORM 4 Code M | $374K5,570 at $67.12 | filing |
| 30 Mar 2022filed 31 Mar 2022 | TGT TargetMass, Grocery & Drug Retail | SEC FORM 4 Code F | $374K1,675 at $223.26 | filing |
| 9 Mar 2022filed 10 Mar 2022 | TGT TargetMass, Grocery & Drug Retail | SEC FORM 4 Code A | —878 at $0.00 | filing |
| 23 Feb 2022filed 25 Feb 2022 | ECL EcolabChemicals | SEC FORM 4 Code A | —34,202 at $0.00 | filing |
| 23 Feb 2022filed 25 Feb 2022 | ECL EcolabChemicals | SEC FORM 4 Code F | $2.6M14,747 at $175.59 | filing |
| 15 Dec 2021filed 6 Jan 2022 | ECL EcolabChemicals | SEC FORM 4 Code G | —26,316 at $0.00 | filing |
| 14 Sep 2021filed 15 Sep 2021 | ECL Ecolaboption or derivative · Chemicals | SEC FORM 4 Code M | —173,036 at $0.00 | filing |
News
Moderna, Merck shares fall on eagerly anticipated cancer vaccine resultsMRK · biopharmadive.com · 22 Oct 2026Merck & Co., Inc. $MRK Stock Sold by Smith Chas P & Associates PA CpasMRK · dailypolitical.com · 22 Oct 202610,147 Shares in Ecolab Inc. $ECL Purchased by Sawyer & Company IncECL · dailypolitical.com · 21 Oct 2026Merck's KEYTRUDA Plus Padcev Wins EU Approval For Muscle-Invasive Bladder CancerMRK · rttnews.com · 21 Oct 2026U.S. Bancorp's Dividend Is Doing Its Job. Can the Stock Do Its Part?USB · insidermonkey.com · 19 Oct 2026Lsb Industries (NYSE:LXU) versus Ecolab (NYSE:ECL) Head-To-Head ComparisonECL · tickerreport.com · 19 Oct 2026U.S. Bancorp Earnings: Ten-Quarter Win Streak Faces the NII TestUSB · 247wallst.com · 15 Oct 2026U.S. Bancorp (USB) Stock Price, News & AnalysisUSB · 247wallst.com · 11 Oct 2026
0 headlines in the last 90 days name Douglas M. Baker Jr.; 8 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.